Answers are grounded in this paper and cite their sources.
Background M2 macrophages contribute to cervical cancer progression and immune regulation within the tumor microenvironment. However, the clinical relevance and prognostic value of M2 macrophage-related genes (MRGs) in cervical cancer remain poorly defined. Methods Weighted gene co-expression network analysis and Pearson correlation analysis of the TCGA-CESC and GSE44001 datasets identified 63 MRGs, which were subjected to functional enrichment analysis. A two-gene prognostic model was developed using univariate Cox regression, least absolute shrinkage and selection operator regression, and multivariable Cox regression. Patients were stratified into high- and low-risk groups according to the median risk score. Survival outcomes, immune cell infiltration, genomic alterations, and anticancer drug sensitivity were compared between groups. PKD2L1 and PILRA expression in cervical cancer and adjacent normal tissues was assessed using quantitative PCR and western blotting. The effects of gene overexpression on cell proliferation and apoptosis were evaluated using Cell Counting Kit-8, colony formation, and flow cytometry assays. The effects of PKD2L1 and PILRA co-expression on tumorigenicity were evaluated in a subcutaneous xenograft model in nude mice. Intratumoral M2 macrophage distribution was assessed using multiplex immunohistochemistry. Results A prognostic model comprising PKD2L1 and PILRA was developed and validated. High-risk patients had significantly poorer survival outcomes than low-risk patients. The risk score remained independently associated with prognosis, and the model showed consistent prognostic performance across clinical subgroups. Gene set enrichment analysis revealed reduced enrichment of immune-related pathways in the high-risk group. CIBERSORT and single-sample gene set enrichment analysis indicated lower immune cell infiltration in this group. High-risk patients also exhibited higher tumor mutational burden and greater genomic instability. Model-derived risk scores were associated with anticancer drug sensitivity. PKD2L1 and PILRA expression was significantly lower in cervical cancer tissues than in adjacent normal tissues. In vitro, overexpression of PKD2L1 and PILRA inhibited cervical cancer cell proliferation, promoted apoptosis, and increased cisplatin sensitivity. In nude mice, overexpression of these genes suppressed xenograft growth and reduced tumor weight. Multiplex immunofluorescence showed that their combined overexpression significantly reduced intratumoral M2 macrophage infiltration. Conclusions The PKD2L1–PILRA prognostic model may support risk stratification and characterize differences in immune infiltration and drug sensitivity in cervical cancer. Functional experiments provide preliminary evidence supporting tumor-suppressive roles for both genes. These findings warrant further investigation of their potential as prognostic biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: